John Wisson
About John Wisson
John Wisson serves as the International Product Director at Lumos Diagnostics, where he has worked since 2019. He has a strong background in product development and marketing within the healthcare sector, particularly in infectious diseases and respiratory health.
Work at Lumos Diagnostics
John Wisson has served as the International Product Director at Lumos Diagnostics since 2019. In this role, he focuses on translating customer insights and market trends into innovative commercial solutions. His responsibilities include overseeing product development and market strategies to enhance the company's international presence.
Previous Experience at Alere Inc.
Prior to his current position, Wisson held multiple roles at Alere Inc. from 2002 to 2017. He served as a Quality Assurance Microbiologist, International Technical Support Manager, and Director of New Product Development for Infectious Diseases. He also worked as the Director of Global Marketing for Respiratory & HAI and played a significant role in developing the Alere i, a CLIA waived Molecular platform.
Educational Background
John Wisson's educational qualifications include a BSc. Hons in Applied Biology (Microbiology) from the University of Hertfordshire, completed between 1992 and 1994. He also studied at Bedford College of Higher Education, earning a BTEC ONC in Medical Laboratory Science, and at Anglia Higher Education College, where he achieved a BTEC HNC in Medical Laboratory Science.
Career in Biomedical Science
Wisson began his career as a Biomedical Scientist in Microbiology at the NHS from 1986 to 1990. This early experience laid the foundation for his extensive career in the diagnostics and medical technology sectors, where he has developed expertise in product management and market development.
Achievements in Product Development
Throughout his career, John Wisson has implemented 'train the trainer' programs to strengthen business partnerships with distributors and marketing affiliates. He has also played a key role in market development initiatives aimed at promoting the rapid adoption of Point of Care Molecular technology for infectious diseases.